← Home
Sanofi 
Pharma / Pharmaceuticals and Healthcare
Press Releases
| Date | Press release |
|---|---|
| 2025-04-30 12:46:00 | Press Release: Annual General Meeting Of April 30, 2025 Annual general meeting of april 30, 2025 approval of the financial statements for the fiscal year 2024 distribution of a cash dividend of €3.92 per share, with payment as of may 14, 2025 board composition: renewal of four directors and ratification of the cooptation of jean-paul kress paris, april 30, 2025. the combined general shareholders’ meeting of sanofi was held on april 30, 2025, under the chairmanship of frÉdÉric oudÉa. |
| 2025-04-30 07:00:00 | Press Release: Sanofi And Cd&r Close Opella Transaction, Create Global Consumer Healthcare Leader Sanofi and cd&r close opella transaction, creat e global consumer healthcare leader paris, april 30, 2025 . opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in sanofi’s strategy. |
| 2025-04-29 07:00:00 | Press Release: When Every Second Counts: Sanofi, Mclaren Racing And United Autosports Join Forces To Raise Meningitis Awareness At Le Mans 24 Hours Race When every second counts: sanofi, mclaren racing and united autosports join forces to raise meningitis awareness at le mans 24 hours race |
| 2025-04-24 01:35:00 | Innate Pharma Announces €15m Investment By Sanofi Marseille, france--(business wire)-- #anket--regulatory news: innate pharma sa (euronext paris: iph; nasdaq: ipha) (“innate” or the “company”) today announces a €14,999,998.59 capital increase subscribed by sanofi. as announced on april 23, 2025, and given the satisfactory market conditions, sanofi has agreed to subscribe to 8,345,387 new ordinary shares of innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 o. |
| 2025-04-24 01:30:00 | Press Release: Sanofi: Strong Q1 Performance And 2025 Guidance Confirmed Sanofi: strong q1 performance and 2025 guidance confirmed paris, april 24, 2025 q1 sales growth of 9.7% at cer 1 and business eps 2 of €1.79 pharma launches reached sales of €0.8 billion, up 43.8%, driven by altuviiio dupixent sales were €3.5 billion, up 20.3% vaccines sales were €1.3 billion, up 11.4%, driven by favorable beyfortus phasing research and development expenses reached €1.8 billion, up 6.9% selling, general and administrative expenses were €2.2 billion, up 3.8% business eps was €1.79, up 15.7% at cer and up 17.0% reported; ifrs eps was €1.52 pipeline continued to deliver six regulatory approvals across medicines in immunology, rare diseases, and oncology recent new data from the mid-stage pipeline unlocks late-stage studies in asthma and skin diseases, broadening and deepening the scope in immunology sustainability strategy updated sustainability strategy focuses on access to healthcare, environmental impact, and resilience of healthcare systems. 70% of the portfolio and >75% of the pipeline target diseases that are impacted by climate and environmental challenges capital allocation the closing of the sale of a controlling stake in opella to cd&r is anticipated in q23 sanofi has agreed to acquire dr-0201, a targeted bispecific myeloid cell engager4 guidance confirmed in 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at cer5. |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal